权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Rapid, Multiplexed, Idealized Antiepileptic Drug Monitoring

快速、多重、理想化的抗癫痫药物监测

基本信息

批准号：
10080343
负责人：
Anna Schibel
金额：
$ 25.86万
依托单位：
ELECTRONIC BIOSCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10080343
关键词：
Affect Antibiotics Antibodies Antiepileptic Agents Antipsychotic Agents Binding Biological Assay Biological Sciences Biosensing Techniques Biosensor Blood specimen Buffers Carbamazepine Charge Chemicals Chemistry Clinical Clinical Chemistry Clinical Pharmacology Collaborations Detection Development Devices Drug Interactions Drug Monitoring Drug Prescriptions Electrolytes Electronics Elements Epilepsy Excision Filtration Foundations Genetic Goals Home environment Immunoassay Immunosuppressive Agents Individual Ions Label Laboratories Letters Mass Spectrum Analysis Measurement Measures Medical Metabolic Methodology Methods Microfluidics Nanotechnology Pathology Patient Care Patient-Focused Outcomes Patients Performance Pharmaceutical Preparations Pharmacogenetics Phase Phenytoin Physiological Plasma Reader Regimen Sampling Serum Side Signal Transduction Speed Surface Systems Integration Technology Testing Therapeutic Time Toxicology Tube Universities Utah Valproic Acid Vial device Whole Blood adverse drug reaction aptamer base biomarker panel care outcomes cost design dosage drug development drug efficacy drug metabolism experience improved individual patient nanofabrication nanopore patient response pharmacokinetics and pharmacodynamics point of care precision medicine professor programs prototype research and development response sensor sensor technology signal processing small molecule specific biomarkers therapeutic evaluation treatment planning voltage

项目摘要

Project Summary Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology and clinical chemistry focused on the measurement of drug concentrations, typically in serum or plasma. Quantifying a drug concentration in the body enables a clinician to tailor/optimize prescribed drug dosages to the individual patient, based on establishing and understanding the associated pharmacokinetic and pharmacodynamic relationships of drug metabolism, which can vary drastically between patients. Thus, TDM is critical toward personalizing patient treatment plans and enabling precision medicine for improved patient care and outcomes. However, there is currently no simple, rapid (<15 min), easy-to-use, and inexpensive device that can accurately measure drug levels from a given sample. In response to this technology gap, during this program, Electronic BioSciences (EBS), in collaboration with a highly interdisciplinary team of field experts, will develop a truly unique, enabling, and state-of-the-art TDM technology that overcomes the known target characterization problems that have plagued the biosensor/immunoassay field for years. During this project, EBS will be focusing specifically on antiepileptic drug monitoring, a subset of TDM that has an urgent and pressing need for improved characterization methods, along with a significant commercial potential for the proposed technology once it is developed. However, it should be noted that the technology and associated methodology developed during this program will be transferable to other TDM applications, including but not limited to antibiotics, immunosuppressants, antipsychotics, etc.

项目总结